psychological symptoms behavior compulsive behavior addiction

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 12, 2024Time:8:30 AM Eastern TimeUnited States:1-877-300-8521International:1-412-317-6026Israel:1-80-921-2373Conference ID:10193781Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1693565&tp_key=866e8470ea The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com. Contacts: BrainsWay:Ido MaromChief Financial OfficerIdo.Marom@BrainsWay.com Investors:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com

Gardena's Premier Destination for Residential, In-Network Treatment GARDENA, Calif., Oct. 17, 2024 /PRNewswire/ -- The vibrant city of Gardena has welcomed an exciting addition to its wellness community with the grand opening of Clear Behavioral Health Residential Rehab Treatment Center. As Clear's 15th location within Los Angeles County, this comprehensive behavioral health facility will serve Gardena, the South Bay, and surrounding areas by providing a residential rehab and detox facility for addiction recovery and dual diagnosis treatment. Continue Reading Step inside Clear Behavioral Health's Residential Rehab Treatment Center in Gardena, CA. Serving Los Angeles County and surrounding areas by providing a residential rehab and detox facility for addiction recovery and dual diagnosis treatment. At this new 20 bed facility, clinicians treat a wide variety of substance use disorders and mental health conditions, including Alcohol/Opiate/Stimulant Use Disorder, Benzodiazepine dependence, dual diagnosis addiction w/ depression, anxiety, trauma, ADHD Staggering statistics forecast that only 28% of eligible Detox/Rehab/RTC individuals, and a mere 11% of eligible PHP/IOP individuals, will receive treatment in 2026. Clear's new facility aims to bridge that gap for those in need of care. The new location expands Clear's treatment capacity by 20 beds, enabling more individuals to receive comprehensive, evidence-based treatment that most major insurance providers cover. At this new Gardena facility, clinicians treat a wide variety of substance use disorders and mental health conditions, including Alcohol Use Disorder, Opiate Use Disorder (heroin, fentanyl, kratom, pain killers), Stimulant Use Disorder (methamphetamine, Adderall, crack/cocaine), Benzodiazepine dependence (Xanax, Klonopin), dual diagnosis disorders including addiction with depression, anxiety, trauma, ADHD, and other mental health diagnoses. Our highly individualized treatment plans are tailored to meet each client's needs at every step of their recovery journey. Dr. Martha B. Koo, MD, Chief Medical Officer and Clinical Supervisor of Clear Behavioral Health, brings unparalleled expertise and passion to addressing mental health solutions through Clear's services. Dr. Koo obtained her psychiatry residency training at the Resnick Neuropsychiatric Institute at UCLA and her subsequent psychoanalytic training at the New Center for Psychoanalysis. She is double Board-Certified in Psychiatry and Addiction Medicine and has over twenty years of psychiatric experience. "Our services at Clear Behavioral Health are designed to be highly individualized, evidence-based, and holistic, ensuring that each client receives care tailored to their unique needs," said Dr. Martha Koo. "We believe in treating the whole person—addressing not just the symptoms of mental health and addiction disorders but also the underlying issues. Our compassionate and experienced staff create a warm, welcoming environment that fosters healing and recovery, empowering individuals to reclaim their lives." Joining Dr. Koo's team as the Clinical Director of Clear's Substance Use Disorder Division is Jason Bernstein, LMFT. Jason holds a master's degree in clinical psychology from Antioch University. With over five years of experience in the substance use and mental health field, he is passionate about supporting individuals seeking dual diagnosis treatment on their journey toward healing, growth, and achieving emotional and psychological wellbeing. His commitment to providing compassionate care and fostering an environment conducive to recovery positions him as a valuable leader for the Gardena facility. "Our inpatient rehab provides the safety and comfort needed for individuals to detox and rehabilitate from addiction while also addressing underlying mental health disorders," said Jason Bernstein. "We are excited to welcome our first clients to Gardena, where we're proud to provide whole-person family-centered care. Every person deserves the opportunity to recover, grow, and live a functional, happy life." The Gardena facility features a home-like, safe, and clinical environment. Program Director Jamie Arthur, CATC, CADC-II, has over 10 years of experience in the substance use recovery field and is dedicated to ensuring clients receive a robust range of program services to launch their recovery. Services include: Round-the-Clock Clinical Staff: Our compassionate team led by Jason Giles, MD, and Brittany Skinner, PMHNP provides 24/7 supervised care. Peer Support: Group therapy sessions foster a sense of unity while providing the space to develop healthy relationships. Medication Management: Safe transitions into detox help patients regain mental and physical stability as comfortably as possible. Therapy and Counseling: Individual therapy and counseling help patients uncover the root of their mental health struggles and develop tools to regain self-trust and balance. Experiential Therapies: Group therapeutic wellness activities such as yoga, meditation and sound healing enhance recovery. In addition to the Gardena launch, Clear Behavioral Health has recently opened facilities in Van Nuys and El Segundo, providing outpatient mental health treatments for adults and teens. These locations offer Intensive Outpatient Programs (IOP), including individual therapy, peer support, holistic therapies, and academic counseling. Founded in 2015, Clear Behavioral Health is a subsidiary of Your Behavioral Health, a leading regional provider of mental health and addiction treatment services for adults and teens, with 28 facilities and growing throughout Southern California. Your Behavioral Health provides the full continuum of behavioral health care, including detox, outpatient (PHP/IOP), interventional psychiatry, and residential care across its family of brands — which includes Clear Behavioral Health, New Life House, and Neuro Wellness Spa — and delivers specialized programs for depression, anxiety, trauma-related issues, addiction and other mental health conditions. Co-founders Mike Joly, Chief Executive Officer, and Dr. Martha Koo, Chief Medical Officer, lead Your Behavioral Health alongside an expert team of clinicians across Southern California. For more information about Clear Behavioral Health or to schedule a free consultation, please visit our website at or call us at 877-564-5571. About Clear Behavioral Health ClClear Behavioral Health, formerly Clear Recovery Center, is a leading Los Angeles-based provider of comprehensive, in-network behavioral health treatment programs. Our mission is simple: to help those struggling with mental health and addiction live healthy and purposeful lives. Our unique story started with a vision to make clinically excellent, highly individualized mental health services accessible to all. For a list of our 15 locations, visit . About Your Behavioral Health Your Behavioral Health is a leading regional behavioral health services platform providing comprehensive, best-in-class services for adults and teens across the continuum of mental health and addiction treatment. With state-of-the-art facilities across Southern California, expert clinical teams, and a pioneering evidence-based approach, Your Behavioral Health offers specialized residential, inpatient, and outpatient programs for a range of mental health conditions. Its family of brands includes Clear Behavioral Health, New Life House, and Neuro Wellness Spa. For more information, please visit . Contact: Stephanie Paz Townsend (310) 295-0429 [email protected] SOURCE Clear Behavioral Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AD04 Program Aligned with NIAAA's New Inclusion of Non-Abstinence Solutions, Validating Commercial and Government Market PotentialGLEN ALLEN, Va., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the National Institute on Alcohol Abuse and Alcoholism (NIAAA) for its newly updated definition of recovery. The new definition, outlined and emphasized in NIAAA’s 2025 Professional Judgement Budget (PJB) as reported to the U.S. Congress following an original introduction in an NIAAA PJB, emphasizes a broader, non-abstinence approach to recovery, which aligns directly with Adial’s AD04 program, which has the potential to offer patients the flexibility of reducing drinking and/or abstinence. NIAAA’s updated definition underscores a growing clinical outcome goal and recognition that effective recovery solutions need not be solely abstinence based, opening the door to therapeutic options that focus on harm reduction and improved quality of life. AD04, Adial’s lead investigational product for alcohol use disorder (AUD), is designed to support patients seeking flexible treatment that could offer reduction in drinking and/or abstinence recovery paths, making it a promising candidate to meet the evolving market needs. This recognition and further emphasis in the FY 2025 Professional Judgement Budget by NIAAA is validation of Adial’s approach as meeting the NIAAA’s new standard for recovery, broadening Adial’s significant commercial and government market potential. “AD04 is uniquely positioned to provide a therapeutic option for those seeking a reduction in alcohol use and/or complete abstinence,” said Cary Claiborne, CEO of Adial Pharmaceuticals. “With NIAAA’s focus shifting to include non-abstinence recovery approaches, we are optimistic that this will stimulate additional support for programs like AD04, not only within commercial markets but also from government initiatives. The alignment of AD04’s development and the NIAAA’s updated perspective offers a promising future for those suffering from AUD, providing them with more personalized, flexible treatment options.” About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com. If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us (BD@adialpharma.com) to discuss how our joint efforts can bring about positive change in the millions of patients who are struggling with addiction. Forward-Looking Statements This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding AD04 supporting patients seeking flexible treatment that could offer reduction in drinking and/or abstinence recovery paths, making it a promising candidate to meet the evolving market needs, the recognition by NIAAA that effective recovery solutions need not be solely abstinence based broadening Adial’s significant commercial and government market potential, AD04 being uniquely positioned to provide a therapeutic option for those seeking a reduction in alcohol use and/or complete abstinence, NIAAA’s focus shifting to include non-abstinence recovery approaches stimulating additional support for programs like AD04, not only within commercial markets but also from government initiatives, the alignment of AD04’s development and the NIAAA’s updated perspective offering a promising future for those suffering from AUD, providing them with more personalized, flexible treatment options and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact:Crescendo Communications, LLCDavid Waldman / Alexandra SchiltTel: 212-671-1020Email: ADIL@crescendo-ir.com